Purpose: The COMPARE (COMparing treatment options for ProstAte cancer) study aimed to
evaluate and quantify the trade-offs patients make between different aspects of active …

Purpose: Specialist bias, in which specialists recommend the therapy that they are capable
of delivering, is thought to influence the treatment of patients with localized prostate cancer …

PURPOSE Overtreatment of screen-detected localized prostate cancer (LPC) is an important
public health concern, since the survival benefit of aggressive treatment (surgery or …

BACKGROUND Selecting treatment for clinically localized prostate cancer remains an
ongoing challenge. Previous decision analyses focused on a hypothetical patient with …

Background: Cancer-specific mortality is projected to be only 1% in 15 years in
approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly …

PURPOSE: We compared health-related quality-of-life (HRQOL) outcomes and survival of
men with localized prostate cancer who received aggressive treatment with those receiving …

Context In the United States, 192 000 men were diagnosed as having prostate cancer in
2009, the majority with low-risk, clinically localized disease. Treatment of these cancers is …

Background Men with early-stage prostate cancer have multiple options that have similar
oncologic efficacy but vary in terms of their impact on quality of life. In low-risk cancer, active …

Purpose: We assessed the effect of age, health status and patient preferences on outcomes
of surgery vs active surveillance for low risk prostate cancer. Materials and Methods: We …

Abstract Treatment choices for localized prostate cancer appear to vary widely, although it is
unclear whether this variation is a result of patient values or other factors. The authors …